Hepatobiliary Surgery

Oct 18, 2024 | karger.com | Maaz Khan |Brian Michael |Juan Pablo |Hepatobiliary Surgery

Introduction: Immune thrombocytopenia (ITP) secondary to durvalumab, a programmed cell death ligand 1 inhibitor, is a rare but clinically significant immune-related adverse event. Herein, we present 2 patients with cholangiocarcinoma who developed ITP immediately post-yttrium-90 radioembolization (Y90-RE) while on durvalumab-based systemic therapy. We hypothesize that given the timing, the immunotherapy and the radioembolization combination led to this event.

Jun 5, 2024 | bmcwomenshealth.biomedcentral.com | Addis Ababa |Hepatobiliary Surgery |Debre Markos

ReferencesZhao ZH, Yao S, et al. Pregnancy-related ICU admissions from 2008 to 2016 in China: a first multicenter report. Crit Care Med. 2018;46(10):e1002. Article  PubMed  PubMed Central  Google Scholar  ACOG Practice Bulletin 211 Summary: critical care in pregnancy. Obstet Gynecol, 2019. 133(5): p. 1063–6. Guntupalli KK, et al. Critical illness in pregnancy: part II: common medical conditions complicating pregnancy and puerperium. Chest. 2015;148(5):1333–45.

Mar 24, 2024 | cancerci.biomedcentral.com | Hepatobiliary Surgery

Human gastric cancer cell lines (AGS, N87) were purchased from the American Type Culture Collection (ATCC), MNK-45 and SGC-7901 were obtained from the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ). Human normal gastric cell line (GES-1) and human 293T cells were purchased from ATCC. Cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich, USA), plus 10% fetal bovine serum (FBS; Gibco, USA). Cells were maintained at 37 ℃ with 5% CO2.

Mar 8, 2024 | academic.oup.com | Hepatobiliary Surgery |Alma Mater Studiorum |New Territories

Many patients with hepatocellular carcinoma (HCC) present with multinodular tumours1. Nodular number predicts the severity of intrahepatic spread and multinodular HCC has been demonstrated to be an important prognostic risk factor after hepatic resection2,3.

Jan 29, 2024 | ejso.com | Mario De Bellis |Hepatobiliary Surgery |Alberto Contro |Andrea Bianco |Alfredo Guglielmi |Giancarlo Mansueto | +3 more

Recurrent or locally advanced peri-hilar cholangiocarcinoma (PHCC) usually involves the portal vein (PV) leading to significant stenosis. With disease progression, clinical symptoms such as ascites, bleeding, and hepatic insufficiency are usually observed. Little is know about the benefit of PV stenting in relieving the symptoms associated to portal hypertension and allowing anticancer therapies. The aim of this study is to review our experience in PV stenting for PHCC patients.